Brain Contains HNK-1 Immunoreactive O-Glycans of the Sulfoglucuronyl Lactosamine Series that Terminate in 2-Linked or 2,6-Linked Hexose (Mannose)*

(Received for publication, September 20, 1996, and in revised form, December 6, 1996)

Chun-Ting Yuen Dagger , Wengang Chai Dagger , R. Wendy Loveless Dagger , Alexander M. Lawson Dagger , Richard U. Margolis § and Ten Feizi Dagger

From Dagger  The Glycosciences Laboratory, Imperial College School of Medicine, Northwick Park Hospital, Harrow, Middlesex, HA1 3UJ, United Kingdom and § The Department of Pharmacology, New York University Medical Center, New York, New York 10016

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

The monoclonal antibody HNK-1 originally raised to an antigenic marker of natural killer cells also binds to selected regions in nervous tissue. The antigen is a carbohydrate that has attracted much interest as its expression is developmentally regulated in nervous tissue, and it is found, and proposed to be a ligand, on several of the adhesive glycoproteins of the nervous system. It is also expressed on glycolipids and proteoglycans, and is the target of monoclonal auto-antibodies that give rise to a demyelinating disease. The epitope, as characterized on glycolipids isolated from the nervous system, is expressed on 3-sulfated glucuronic acid joined by beta 1-3-linkage to a neolacto backbone. Here we exploit the neoglycolipid technology, in conjunction with immunodetection and in situ liquid secondary ion mass spectrometry, to characterize HNK-1-positive oligosaccharide chains derived by reductive alkaline release from total brain glycopeptides. The immunoreactive oligosaccharides detected are tetra- to octasaccharides that are very minor components among a heterogeneous population, each representing less than 0.1% of the starting material. Their peripheral and backbone sequences resemble those of the HNK-1-positive glycolipids. An unexpected finding is that they terminate not with N-acetylgalactosaminitol but with hexitol (2-substituted and 2,6-disubstituted). In a tetrasaccharide investigated in the greatest detail, the hexitol is identified as 2-substituted mannitol.


INTRODUCTION

Monoclonal antibodies raised with the aim of identifying developmentally regulated antigens and differentiation antigens that have biological functions are in many cases directed to oligosaccharides of glycoproteins or glycolipids (1). Prominent among such antigens are those based on backbone sequences of the poly-N-acetyllactosamine type that are O- or N-glycosidically linked to proteins or to a glucose core of glycolipids (1, 2), several of which are now established ligands for carbohydrate-binding proteins of animals (3-6); and there is much interest in the biological events elicited by the carbohydrate-protein interactions. HNK-1 antigen, recognized by a hybridoma antibody, is a carbohydrate antigen first identified as a marker of the natural killer cell population among lymphocytes (7), and later found to be expressed on glycolipids (8-10) as well as several glycoproteins (11) and proteoglycans (12) of the nervous system, with a changing distribution at different stages of development (13-15). HNK-1 antigen, as characterized biochemically on glycolipids, is expressed on 3-sulfated glucuronic acid joined by beta 1-3-linkage to a (poly)N-acetyllactosamine backbone (8-10). This carbohydrate sequence has been implicated as a ligand for the leukocyte-endothelium adhesion molecules, L- and P-selectins (16, 17) and for a number of cell-interaction systems in nervous tissue (11, 18), notably as a ligand for the major glycoprotein of myelin, Po, in the peripheral nervous system (19), the extracellular matrix protein, laminin (20), and an adhesive protein, amphoterin, of the cerebellum (21). Earlier indications of the presence of the HNK-1 antigen on N-glycosidically linked oligosaccharides (22-24) have now been followed by structural studies demonstrating the presence of the 3-sulfoglucuronyl N-acetyllactosamine sequence on a N-glycan isolated from glycoprotein Po (25). Biosynthetic experiments suggest that different glucuronyltransferases are involved in the synthesis of the HNK-1 epitope on glycolipids and glycoproteins (26).

The present investigation is concerned with HNK-1-immunoreactive oligosaccharides among total brain glycopeptides. In exploratory experiments, oligosaccharides were released by hydrazinolysis to obtain N-glycosidically linked chains, and by reductive and non-reductive alkaline hydrolysis to obtain O-glycosidically linked chains; these were examined for immunoreactivities after conversion to neoglycolipids. Having observed immunoreactive oligosaccharides among all three oligosaccharide populations, a more detailed investigation has been performed of oligosaccharides released by reductive alkaline hydrolysis.


MATERIALS AND METHODS

Glycopeptides

Glycopeptides were prepared from a Pronase digest of a lipid-free protein residue (chloroform-methanol extract) of rabbit brain, after precipitation of glycosaminoglycans with cetylpyridium chloride (27).

Oligosaccharides

In small scale experiments, oligosaccharides were obtained from 10-mg aliquots of brain glycopeptides by three methods. (i) O-Glycosidic oligosaccharides in reducing form were obtained after subjecting the glycopeptides to hydrolysis with ethylamine (70% w/v in water) at 60° C for 6 h as described (28). The oligosaccharide-rich fraction was N-acetylated using acetic anhydride (29) to acetylate free amino groups of any residual peptide materials that might interfere with the reductive amination reaction in the generation of neoglycolipids. (ii) O-Glycosidic oligosaccharides in reduced form were obtained after subjecting the glycopeptides to hydrolysis with 0.05 M NaOH, 1 M NaBH4 at 45 °C for 16 h as described (30), and the oligosaccharide-rich fraction was N-acetylated (29). (iii) N-Glycosidic oligosaccharides in reducing form were obtained after treatment of the glycopeptides with anhydrous hydrazine for 9 h (29). In a larger scale experiment, O-glycosidic oligosaccharides in reduced state were obtained from 600-mg glycopeptides after reductive alkaline hydrolysis (30).

Oligosaccharide Standards

Sulfated tri-, tetra-, and pentasaccharides of the Lea series were synthesized chemically: HSO3-3Galbeta 1-3(Fucalpha 1-4)GlcNAc and HSO3-3Galbeta 1-3(Fucalpha 1-4)GlcNAcbeta 1-3Gal (31) were gifts of Dr. K. C. Nicolaou (Scripps Research Institute, La Jolla, CA) and HSO3-3Galbeta 1-3 (Fucalpha 1-4)GlcNAcbeta 1-3Galbeta 1-4Glc (32) was a gift of Dr. A. Lubineau (University Paris, Orsay, France). Manalpha 1-2Man and Fucalpha 1-2Gal were from BioCarb through Russell Fine Chemicals (Chester, United Kingdom) and Glcalpha 1-2Glc was from Dextra Laboratories (Reading, United Kingdom). These disaccharides were reduced with NaBH4 (29).

Fractionation of Oligosaccharides

Oligosaccharides obtained in each of the small scale experiments were fractionated on DEAE Sephadex A-25 (0.75 ml, acetate form, Pharmacia) into neutral fractions, 1.5 ml (unretained with 10 mM NH4OAc, pH 5) and acidic fractions, 3 ml (eluted with 500 mM NH4OAc, pH 5); these were designated as N and A, respectively. Fractions A were treated with Arthrobacter ureafaciens sialidase (Boehringer Mannheim) and further fractionated as above into neutral (Ns) and sialidase-resistant acidic fractions: As1, and As2 eluted with 100 and 500 mM NH4OAc, respectively. Oligosaccharides recovered are summarized in Table I. An aliquot of oligosaccharides As2 (26 µg of hexose) from the ethylamine hydrolysis experiment was further fractionated by isocratic elution on a normal phase HPLC1 column (TSK amide-80, 4.6 × 250 mm, Anachem, United Kingdom) using 70% acetonitrile/water in 10 mM sodium acetate, pH 5.3, at a flow rate of 1 ml/min. Eight fractions (1.5 ml each), designated As2 a-h, were collected after 2 min of flow, and desalted using AG 50W X-12 H+ (Bio-Rad); whole fractions were converted to neoglycolipids, and 10% aliquots of the neoglycolipid reaction mixtures tested for HNK-1 immunoreactivity.

Table I.

Oligosaccharides recovered in the small scale experiments

N and A are neutral and acidic fractions, respectively, obtained after anion exchange chromatography, and Ns. As1, and As2 are a neutral and two acidic fractions generated from sialidase-treated fraction A as described under "Materials and Methods."


Method Oligosaccharides
Total N A Ns As1 As2

µg hexose
Ethylamine 733 188 534 341 119 51a
Alkaline borohydride 1220 227 836 609 129 47
Hydrazine 1774 382 1267 887 172 63

a Twenty-six µg of oligosaccharide fraction As2 (determined as hexose) from the ethylamine experiment was subfractionated into eight fractions (a-h) by normal phase HPLC as described under "Materials and Methods"; fraction g with the strongest HNK-1 immunoreactivity as neoglycolipids was subjected to TLC-LSIMS.

Saccharides released in the large scale reductive alkaline hydrolysis experiment were initially resolved by two chromatographic steps using Bio-Gel columns (1.5 × 100 cm; Bio-Rad) essentially as described (33) except that 2 mM trifluoroacetic acid was used as eluent at ambient temperature. Bio-Gel P-6 was used to separate high molecular weight materials located at the void volume from the smaller sized retained fractions, eluting between 61 and 150 ml. The retained fraction, 80.3 mg of hexose, was concentrated by evaporation and fractionated on Bio-Gel P-4. Seven pooled fractions were obtained (Fig. 1): 1) 0.5 mg; 2) 3.1 mg; 3) 5.5 mg; 4) 3.6 mg; 5) 13.4 mg; 6) 52.0 mg; and 7) 1.7 mg, determined as hexose. Aliquots of these pooled fractions (5 µg of hexose) were converted to neoglycolipids and tested for HNK-1 immunoreactivity (Fig. 2). The pooled Bio-Gel P-4 fractions 1, 2, and 3 which showed strong HNK-1 immunoreactivities were chromatographed on a weak anion exchange polymeric HPLC column (Asahipak NH2-P50, 4.6 × 250 mm, Prolabo, United Kingdom) using a start solvent: 2.5 mM NH4OAc, pH 6.8, and eluting with 0-250 mM NH4OH, pH 11.7 (Fig. 3). A neutral fraction eluting with the start solvent and two acidic fractions eluting at about 80 and 150 mM NH4OH were obtained, and designated N, A1, and A2, respectively (for example 1N, 1A1, and 1A2 for the three subfractions of Bio-Gel P-4 pool 1). Aliquots of these fractions (5 µg of hexose) were converted to neoglycolipids and tested for HNK-1 immunoreactivities as neoglycolipids (results not shown). In each set, fraction A2 showed HNK-1 immunoreactivity and was further fractionated by gradient elution on a normal phase TSK amide-80 HPLC column as above using acetonitrile/water in 2 mM trifluoroacetic acid (Fig. 4). Aliquots of these chromatographic fractions (1 µg of hexose) were monitored for HNK-1 immunoreactivities as neoglycolipids. From each of the A2 oligosaccharide fractions, three HNK-1 immunoreactive subfractions were obtained (Fig. 4): 1Ab, 1Ac, and 1Ad; 2Ac, 2Ad, and 2Ae; and 3Ad, 3Ae, and 3Af; the oligosaccharides recovered in terms of micrograms of hexose are given in Table II.


Fig. 1. Bio-Gel P-4 chromatography profile of saccharides released by reductive alkaline hydrolysis of brain glycopeptides in the large scale experiment. Oligosaccharides in the retained volume after Bio-Gel P-6 chromatography were chromatographed on a Bio-Gel P-4 column using 2 mM trifluoroacetic acid as solvent. Elution of oligosaccharides (900 µl/fraction) was monitored by assays of hexose concentration. The numbered arrows indicate positions of glucose oligomer standards. Seven pooled fractions were obtained as indicated; shading indicates HNK-1 immunoreactivity detected in neoglycolipids prepared from aliquots of the pooled fractions (see Fig. 2).
[View Larger Version of this Image (26K GIF file)]



Fig. 2. Antibody binding assay to reveal HNK-1 immunoreactivity among neoglycolipids prepared from the pooled oligosaccharide alditol fractions 1 to 7 obtained in the large scale experiment. The neoglycolipid reaction mixtures derived from the Bio-Gel P-4 fractionated oligosaccharides containing 1 µg of hexose were chromatographed in solvent B, revealed by primulin stain (panel p), and thereafter, overlaid with monoclonal antibody HNK-1, and binding detected with 125I-labeled anti-mouse immunoglobulins and autoradiography (panel h) as described under "Materials and Methods." Arrow indicates positions of sample applications.
[View Larger Version of this Image (68K GIF file)]



Fig. 3. Anion exchange HPLC elution profiles of three of the immunoreactive oligosaccharide alditol pools 1, 2, and 3 in the large scale experiment. Oligosaccharide alditol pools 1, 2, and 3: 400, 3100, and 5500 µg of hexose, respectively, obtained after Bio-Gel P-4 chromatography, were subjected to HPLC on an anion exchange polymeric column. Fractions were pooled as indicated (designated N, A1, and A2). Elution profile for pool 1 is that of a single chromatography run that was performed with this pool; profiles for pools 2 and 3 are representative traces of the elution profiles of one of four runs for each pool.
[View Larger Version of this Image (24K GIF file)]



Fig. 4. Normal phase HPLC elution profiles of acidic A2 fractions of the oligosaccharide alditol pools 1, 2, and 3. The HNK-1 immunoreactive acidic oligosaccharide alditol fractions 1A2, 2A2, and 3A2: 220, 262, and 880 µg of hexose, respectively, were subjected to normal phase HPLC and fractions were pooled as indicated; the entire subfraction a of 1A2, and 1 µg (hexose) of the other subfractions were converted to neoglycolipids, and assayed for HNK-1 immunoreactivity as shown in Fig. 6. Pooled fractions a, as well as a part of pooled fraction b of 3A2 are not shown. Black boxes indicate strong HNK-1 immunoreactivity, striped boxes show medium immunoreactivity, and dotted boxes indicate weak immunoreactivity.
[View Larger Version of this Image (25K GIF file)]


Table II.

Oligosaccharide alditols recovered in three of the seven pooled Bio-Gel P4 fractions (1, 2, and 3), and in their subfractions derived after anion exchange HPLC (N, A1, and A2) and after normal phase HPLC of each of the immunoreactive A2 fractions (a-f)


Fraction Total Oligosaccharides
N A1 A2 a b c d e f

µg hexose
1 400 91 35 220 <1 17 25 56
2 3100 2000 160 262 4 16 32 23 28
3 5500 1290 1460 880 3 165 542 28 30 44

Hexose Assay

The hexose contents of oligosaccharides were estimated by a micro-scale procedure on silica gel plates by applying as spots onto the plates 1 µl of test samples and galactose standards at 0.05-1.0 mg/ml, and staining with orcinol reagent (34).

Neoglycolipids

Neoglycolipids of reducing oligosaccharides and the reduced oligosaccharides were prepared as described previously, incorporating a mild periodate oxidation step with the reduced oligosaccharides (34), and using L-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) from Sigma in the small scale experiments. L-1,2-Dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE) from Fluka was used in the large scale experiments to avoid the traces of monoacyl products that are formed when DPPE is used (34). The reaction mixtures were resolved on HPTLC Silica Gel 60 plates (Merck, BDH) using chloroform/methanol/aqueous, 0.2% CaCl2 (v/v): 60/30/6 (solvent A) or 55/45/10 (solvent B) as indicated, and subjected to primulin staining (34) to reveal lipid-containing components.

Liquid Secondary Ion Mass Spectrometry (LSIMS) and TLC/LSIMS Analyses

LSIMS analyses were carried out as described previously (35, 36). Native oligosaccharides (~1 µg) were analyzed after applying onto the target using thioglycerol as liquid matrix and neoglycolipids were analyzed directly on chromatograms after TLC.

Methylation Analysis

For methylation analysis of oligosaccharides, permethylation (37), hydrolysis, reduction, acetylation, and gas chromatography-mass spectrometry analysis were performed as described previously (38). A modification was introduced into the procedure to include reduction of carboxymethyl groups (39) after permethylation to detect uronic acid residues as their hexitols.

The retention time of -2Manol was established from the partially methylated alditol acetate standard prepared from the disaccharide alditol Manalpha 1-2Manol. This was differentiated from -3Manol, -2Galol, and -2Glcol prepared from Manalpha 1-3Manol, Fucalpha 1-2Galol, and Glcbeta 1-2Glcol, respectively; the retention times being 10.03, 9.81, 10.07, and 10.32 min for partially methylated alditol acetate of -3Manol, -2Glcol, -2Manol, and -2Galol, respectively.

Antibody Binding Assays

Hybridoma cells secreting the HNK-1 monoclonal antibody (7) were obtained from the American Type Culture Collection (Rockville, MD), and antibody containing ascites fluid was produced by standard procedures following inoculation of BALB/c mice. Antibody binding to neoglycolipids chromatographed on HPTLC plates was assayed as described (40), using a 1:500 dilution of ascites overlaid at room temperature for 2 h. 3-Sulfoglucuronyl neolactotetraosylceramide (HNK-1 glycolipid) isolated from bovine cauda equina (a gift of Dr. F. B. Jungalwala; Eunice Kennedy Shriver Center, Waltham, MA) was used as a positive control.


RESULTS

Small Scale Experiments

In antibody binding experiments using the neoglycolipids obtained in the small scale experiments, HNK-1 immunoreactivities were observed predominantly in the most acidic fractions, As2 (Fig. 5), and not in the neutral fractions N and Ns (not shown). The binding was to minor components which showed negligible primulin staining (not shown). Among the neoglycolipids derived from the reducing oligosaccharides released by hydrolysis with ethylamine, multiple immunoreactive components were detected, chromatographing in the tri-/tetrasaccharide and higher oligomer regions. In the same chromatogram binding experiment, using neoglycolipids derived from acidic oligosaccharides released by hydrazinolysis, immunoreactivity was observed just above the point of application (this is the position of migration of neoglycolipids derived from multi-antennary N-glycosidic oligosaccharides),2 and at a position corresponding to tri-/tetrasaccharide neoglycolipids. The hydrazine-released oligosaccharides were not investigated further in the present study.


Fig. 5. Chromatogram binding assays showing HNK-1 immunoreactivities among neoglycolipids derived from brain glycopeptides. Acidic, sialidase-treated oligosaccharides As1 and As2 obtained from brain glycopeptides in the small scale experiments were converted to neoglycoplipids, chromatographed in solvent A, and overlaid with monoclonal antibody HNK-1, and binding detected by autoradiography as described in the legend to Fig. 2. Lanes As1 and As2 contained neoglycolipid reaction mixtures derived from oligosaccharides containing 1 µg of hexose; lane H contained 2 ng (dry weight) of the HNK-1 glycolipid as a positive control. Arrow indicates positions of sample applications. In the left-hand panel, a and b refer to positions on the chromatogram which yielded informative data in TLC-LSIMS analyses, as described under "Results." S3, S4, and S5 are positions of migration of sulfated Lea tri-, tetra-, and pentasaccharides used as standards. The immunostaining data in the left and middle panels are from the same experiment and the right panel from a separate experiment.
[View Larger Version of this Image (43K GIF file)]


TLC-LSIMS analyses of the HNK-1 immunoreactive neoglycolipids derived from subfraction g of fraction As2 (Table I) of the ethylamine-released oligosaccharides gave [M - H]- ions at m/z 1475 (position a, Fig. 5), and m/z 1840 (position b), consistent with the compositions HSO3·HexA·Hex2·Hex NAc·DPPE and HSO3·HexA·Hex3·HexNAc2·DPPE, respectively (results not shown). These findings, with the evidence in each case for the presence of an additional hexose, suggested the presence of the HNK-1 epitope on oligosaccharides having reducing-end hexose residues that may have been generated by peeling of O-glycosidic oligosaccharides. Having detected HNK-1 positive components among oligosaccharides in the small scale reductive experiment (Fig. 5), a larger scale alkaline borohydride reaction was undertaken to minimize peeling.

Large Scale Experiments

General Features of the Immunoreactive Oligosaccharide Alditols

When converted to neoglycolipids after periodate oxidation, the oligosaccharide alditol fractions 1A2c and d yielded a triplet of strongly immunoreactive components i, ii, and iii and a weakly immunoreactive component, iv (Fig. 6). Fractions 2A2c, d, and e and 3A2d, e, and f also yielded immunoreactive components at positions i and ii, but in addition there were components with decreasing mobilities v, vi, and vii in fraction 2A2, and vii, viii, and ix in 3A2 (Fig. 6).


Fig. 6. Chromatogram binding assays showing HNK-1 immunoreactivities among neoglycolipids prepared from subfractions of the acidic oligosaccharide alditol fractions 1A2, 2A2, and 3A2 that had been separated by normal phase HPLC. Aliquots of subfractions a-d of 1A2, a-e of 2A2, and a-f of 3A2, obtained after normal phase HPLC (see Fig. 4) were converted to neoglycolipids. The neoglycolipid reaction mixtures (0.2-0.3 µg of hexose) were chromatographed in solvent B, revealed by primulin stain (panels p), overlaid with monoclonal antibody HNK-1, and binding detected by autoradiography (panel h) as described in the legend to Fig. 2. Results of subfractions a which were not immunoreactive are not shown. Positions of immunoreactive bands are designated i to ix. Arrows indicate positions of sample applications.
[View Larger Version of this Image (38K GIF file)]


The acidic oligosaccharide alditol fractions 1A2c, 2A2d, and 3A2f with the strongest HNK-1 immunoreactivities as neoglycolipids (Figs. 4 and 6) were selected for negative ion LSIMS analyses as the free oligosaccharides. They were deduced to contain sulfated tetra- to octasaccharides with uronic acid in five of seven of them (Table III) as follows. The mass spectrum of 1A2c with [M - H]- at m/z 802 and a fragment ion (loss of 80 Da) at m/z 722 (Fig. 7) was consistent with that of a reduced tetrasaccharide HSO3·HexA·Hex2·HexNAc. This composition is the same as that of one of the components detected as a neoglycolipid (at position a, Fig. 5) among ethylamine-released oligosaccharides. Oligosaccharide analogs of 1A2c containing an additional HexNAc and additional Hex·HexNAc were deduced to be in fraction 2A2d; the latter corresponded to the immunoreactive component detected (at position b, Fig. 5) in the ethylamine experiment. Analogs of 1A2c with additional Hex2·HexNAc2 and dHex·Hex2·HexNAc were deduced to be in fraction 3A2f and the other oligosaccharide alditols to contain sulfate, dHex·Hex3·HexNAc (fraction 2A2d) and dHex·Hex4· HexNAc2 (fraction 3A2f). On account of its relative homogeneity, fraction 1A2c was investigated in the greatest detail as follows.

Table III.

The [M - H]- ions and deduced monosaccharide compositions for the underivatized forms of the three oligosaccharide alditol fractions which showed the strongest HNK-1 immunoreactivity when examined as neoglycolipids


Fraction [M - H]- Composition

1A2c 802 HSO3·HexA·Hex2·HexNAc
2A2d 917 HSO3·dHex·Hex3·HexNAc
1005 HSO3·HexA·Hex2·HexNAc2
1167 HSO3·HexA·Hex3·HexNAc2
3A2f 1282 HSO3·dHex·Hex4·HexNAc2
1458 HSO3·HexA·dHex·Hex4·HexNAc2
1532 HSO3·HexA·Hex4·HexNAc3


Fig. 7. Negative ion mass spectra of underivatized oligosaccharide alditol subfraction 1A2c and immunoreactive neoglycolipid band ii derived from 1A2c after mild periodate oxidation. Top panel shows the mass spectrum of the non-derivatized oligosaccharide alditol 1A2c, and the lower panel shows the mass spectrum of 1A2c neoglycolipid. An ion at m/z 1357 indicates the presence of a small amount of band i neoglycolipid containing the C3H5OH hexitol remnant (see Table III).
[View Larger Version of this Image (22K GIF file)]


TLC-LSIMS Analyses of the Immunoreactive 1A2c Neoglycolipids

The 1A2c-derived triplet of immunoreactive neoglycolipid bands i, ii, and iii (Fig. 6) gave [M - H]- ions at m/z 1357, 1387, and 1417, respectively (Table IV; see also Fig. 7 for band ii). Band iv gave too weak a spectrum for interpretation. The 30-Da differences in the molecular ions derived from bands i to iii are indicative of increments of CHOH arising from different positions of periodate cleavage of a terminal hexitol residue at consecutive C-C bonds (41). This is illustrated for 2-substituted mannitol3 in Scheme 1, where R = oligosaccharide and the resulting neoglycolipids contain remnants of the reduced hexitol with three, four, or five carbons. On this basis, and the deduced composition of the free, non-oxidized oligosaccharide alditol 1A2c (Table III), the [M - H]- ions of the triplet of neoglycolipids were interpreted to arise from neoglycolipids with the composition HSO3·HexA·Hex·HexNAc-X-DHPE, where X = the hexitol-derived fragments, C3H5OH (band i), C4H6(OH)2 (band ii), and C5H7(OH)3 (band iii).

Table IV.

Molecular and fragment ions in the mass spectra, and the deduced compositions or sequences of the neoglycolipid bands shown in Fig. 6, that were bound by HNK-1 antibody


Band [M - H]- Fragmentations Composition/sequencea

1A2c i 357 1277, 1101, 939 HSO3-HexA·Hex·HexNAc-OC3H5(OH)-DHPE
ii 1387 1307, 1131, 969 HSO3-HexA-Hex-HexNAc-OC4H6(OH)2-DHPE
iii 1417 HSO3·HexA·Hex·HexNAc-OC5H7(OH)3-DHPE
iv NDb
2A2d i/ii 1327 HSO3·HexA·Hex·HexNAc-OC2H4-DHPE
1357 HSO3·HexA·Hex·HexNAc-OC3H5(OH)-DHPE
v ND b
vi 1752 1672, 1496 HSO3-HexA-(Hex·HexNAc)2-OC4H6(OH)2-DHPE
vii 1782 HSO3·HexA·(Hex·HexNAc)2-OC5H7(OH)3-DHPE
3A2f i/ii 1327 HSO3·HexA·Hex·HexNAc-OC2H4-DHPE
1357 1277, 1101, 939 HSO3-HexA-Hex-HexNAc-OC3H5(OH)-DHPE
viii 1868 HSO3·HexA·(dHex·Hex2·HexNAc2)-OC3H5(OH)-DHPE
1898 1818, 1642 HSO3-HexA-(dHex·Hex2·HexNAc2)-OC4H6(OH)2-DHPE
ix 2087 HSO3·HexA·(Hex·HexNAc)3-OC3H5(OH)-DHPE
2117 HSO3·HexA·(Hex·HexNAc)3-OC4H6(OH)2-DHPE
2147 HSO3·HexA·(Hex·HexNAc)3-OC5H7(OH)3-DHPE

a Sequences given by mass spectra are indicated by dashes; where sequence information was not obtained, the components are separated by periods. The set of hexitol fragments in bands i, ii and iii derived from oligosaccharide alditol 1A2c, depicted by -OC3H5OH, -OC4H6(OH)2, and -OC5H7(OH)3, respectively, are the predicted periodate oxidation products of 2-substituted hexitol (the same applies for fragments from 2A2d in bands vi and vii, and from 3A2f in bands viii and ix); fragments in bands at positions i/ii derived from alditols 2A2d and 3A2f, depicted by -OC2H4 and -OC3H5OH, are predicted products of 2,6-disubstituted hexitol.
b ND, not determined.


[View Larger Version of this Image (9K GIF file)]

Scheme 1.

A partial sequence, HSO3·HexA·Hex-, was deduced for the neoglycolipid band i from the fragment ions in its spectrum at m/z 1277, 1101, and 939 (Table IV). This, together with the evidence given above for the presence of a terminal hexitol, indicated that band i had the linear sequence HSO3·HexA·Hex·HexNAc·C3H5(OH)-DHPE. Also, the spectrum for band ii (Fig. 7), was consistent with the nonreducing terminal sequence HSO3·HexA·Hex. Therefore, the likely sequences of bands ii and iii were considered to be HSO3· HexA·Hex·HexNAc·C4H6(OH)2·DHPE and HSO3·HexA·Hex· HexNAc·C5H7(OH)3·DHPE, respectively, and the original sequence of the main component in 1A2c before periodate oxidation was assigned as HSO3·HexA·Hex·HexNAc·Hexol.

Linkage and Composition Analyses of the Oligosaccharide Alditol 1A2c

Monosaccharide composition and linkage information on the major component in 1A2c was obtained by methylation analysis of the free oligosaccharide alditol preparation. The results showed -3GlcA1-, -3Gal1-, -4GlcNAc1-, and -2Manol, in the form of the partially methylated alditol acetates 2,4-di-O-methylglucitol, 2,4,6-tri-O-methylgalactitol, 3,6-di-O-methyl-2-N-methyl-acetamidoglucitol, and 1,3,4,5,6-penta-O-methylmannitol, respectively. With these and the mass spectrometric data the main oligosaccharide in fraction 1A2c is assigned as: HSO3-3GlcA1-3Gal1-4GlcNAc1-2Manol.

TLC-LSIMS Analyses of the Immunoreactive 2A2d and 3A2f Neoglycolipids

Of the immunoreactive neoglycolipid bands derived from 2A2d and 3A2f, the bands at i/ii position (Fig. 6) gave the same [M - H]- ion, m/z 1357, as that from 1A2c band i with the three carbon-containing hexitol remnant (Table IV). A small ion was also present at m/z 1327 corresponding to an analog with a two carbon-containing remnant. The presence of the tetrasaccharide-derived neoglycolipids at positions i/ii originating from alditol fractions 2A2 and 3A2 are unlikely to reflect an incomplete separation of the tetrasaccharide in the adjacent fractions 1, 2, and 3 during the Bio-Gel P-4 chromatography step. A more likely explanation is that a proportion of the 2A2 and 3A2 alditols are branched at the terminal hexitol, and the periodate oxidation cleavage is limited to two rather than three C-C bonds as shown in Scheme 2 for 2,6-disubstituted mannitol,4 where R and R' are oligosaccharides.


[View Larger Version of this Image (13K GIF file)]

Scheme 2.

Thus the mass spectra indicated that the bands at i/ii positions were derived by a cleavage of a 2,6-branched hexitol (cf. Scheme 2) with the HSO3·HexA·Hex·HexNAc sequence linked at the 6-position. The neutral neoglycolipids that would be predicted to arise from the 2-linked branch were not specifically searched for in the present study by scanning of the di- to tetrasaccharide regions. However, the compositions of the non-oxidized penta-, hexa-, and octasaccharide alditols with [M - H]- ions 1005, 1167, 1458, and 1532 (Table III) are consistent not only with unbranched 2-hexitol-terminating sulfated sequences, but also with the presence of non-sulfated outer arms consisting of HexNAc, Hex·HexNAc, dHex·Hex·HexNAc, and Hex2·HexNAc2, respectively, 2-linked to terminal hexitols that also bear 6-linked sulfated outer arms.

Of the slower migrating triplet of bands derived from 2A2d, band v gave too weak a spectrum for interpretation, while bands vi and vii gave [M - H]- ions at m/z 1752 and 1782, respectively (Table IV). These correspond to higher molecular mass analogs of neoglycolipid bands ii and iii derived from 1A2c, but 365 Da higher, indicating in each case, the presence of an additional disaccharide unit, Hex·HexNAc. Fragment ions m/z 1672 and 1496 from band vi showed a terminal sulfated HexA residue, and thus provided partial sequence HSO3-HexA. Bands vi and vii are deduced to have been derived from a hexitol-terminating polylactosamine-type analog of 1A2c.

Of the slowest migrating duplex of immunoreactive bands viii and ix from 3A2f, the former gave an [M - H]- ion at m/z 1898, and fragment ions m/z 1818 and 1642 which indicated the presence of a sulfated terminal HexA residue and provided composition information and the partial sequence HSO3·HexA- (Table IV). An [M - H]- ion at m/z 1868 was also present in this band and allowed assignment of composition. Band ix gave two [M - H]- ions at m/z 2117 and 2147; these are 365 Da higher than those from bands vi and vii, respectively, and consistent in each case, with the presence of an additional lactosamine-type disaccharide, Hex·HexNAc. Collectively, these data with 2A2d and 3A2f neoglycolipids, together with the mass spectra from the parent non-oxidized oligosaccharide alditols (Table III), indicate that these HNK-1 immunoreactive hexa- and octasaccharides are a population of polylactosamine-type glycans terminating in 2-substituted hexitol which upon oxidation is cleaved to produce remnants of the reduced hexitol with three, four, or five carbons (Scheme 1, Table IV).


DISCUSSION

This investigation illustrates the power of the neoglycolipid technology to detect and biochemically characterize bioactive oligosaccharides that are extremely minor components of a heterogeneous population. It has enabled total glycopeptide-derived oligosaccharides from brain, a sample size of 80 mg of hexose, to be monitored for immunoreactivities during successive chromatographies, and provided critical information on sequence and linkage by in situ TLC-LSIMS analyses of discrete immunoreactive components that represent as little as 0.03% of the starting oligosaccharides.

The small scale experiments indicated that both N- and O- glycosidic oligosaccharides contain the HNK-1 determinant. The present study is focused on the immunoreactive oligosaccharides obtained by reductive alkaline hydrolysis, the procedure of choice for releasing O-glycosidic, N-acetylgalactosamine-terminating oligosaccharides with minimal peeling (30). The majority of these were found to be tetra- to octasaccharides. Their peripheral and backbone sequences resembled those of the HNK-1-positive glycosphingolipids isolated from nervous tissue (8, 9) in being of the 3-sulfoglucuronyl lactosamine series. Among the oligosaccharides obtained under non-reductive conditions, using ethylamine or hydrazine, there was immunoreactivity of neoglycolipids chromatographing as trisaccharides. These are likely products of peeling as they were not detected among the oligosaccharides isolated under the reductive conditions (Fig. 4). There was evidence for the presence of a deoxyhexose residue in one of the immunoreactive hexasaccharides released from the brain glycopeptides. With the amounts available, however, the precise location of this presumed fucose residue along the oligosaccharide chain has not been established.

Not all of the sulfated oligosaccharides identified in the non-derivatized fractions 2A2d and 3A2f were uronic acid-containing (Table III): two of the deoxyhexose containing sulfated oligosaccharides, one in 2A2d and another in 3A2f, were lacking in uronic acid, and compositionally they resembled the oligosaccharides identified previously among oligosaccharides from brain chondroitin sulfate proteoglycans (42). These were not detected, however, among the immunoreactive neoglycolipids derived from fractions 2A2d and 3A2f.

In studies which will be described elsewhere, N-acetylgalactosaminitol-terminating oligosaccharides have been detected, as expected, by methylation analyses in Bio-Gel P-4 fractions 1 to 4. It is unexpected, however, to find that the immunoreactive oligosaccharides in fractions 1, 2, and 3 are hexitol-terminating, some 2-substituted and others 2,6-disubstituted. In oligosaccharide 1A2c the hexitol was identified as 2-substituted mannitol. In fraction 3, additional mannitol-terminating oligosaccharides Gal1-4GlcNAc1-2Manol and Gal1-4/3(Fuc1-3/4)GlcNAc1-2Manol have been identified after purification and methylation analyses (not shown). Moreover, a recent report describes an analog of the former oligosaccharide 3-sialylated at galactose among the oligosaccharides isolated from the Schwann cell glycoprotein alpha -dystroglycan (43). This raises important questions as to the origins of this family of hexitol-terminating oligosaccharide alditols. Are they peeled products of N-glycosidic oligosaccharides? Or are they members of an unusual family of O-glycosidic oligosaccharides linked to protein via mannose residues, of the type previously described to occur among oligosaccharides released by reductive alkaline degradation from glycopeptide domains of brain proteoglycans (44)? In the studies which will be described elsewhere, oligosaccharides of N-glycosidic type with intact chitobiosyl cores have been detected among the pooled Bio-Gel P-4 fractions; these are of high-mannose type in fractions 4 and 5 and complex type in fraction 5; these findings are consistent with evidence reviewed in Ref. 45 that at least 10-20% of N-glycosidic oligosaccharides are released from protein after alkaline borohydride degradation. In the present investigation, however, no evidence has been found for the presence of peeled products of N-glycosidic oligosaccharides with loss of one or two of the N-acetylglucosamines of the chitobiosyl core, or other intermediate products of sequential degradation among the Bio-Gel P-4 fractions. Moreover, in separate investigations2 when a purified, asialo-biantennary N-glycosidic oligosaccharide (100 µg) was subjected to the reductive alkaline borohydride treatment, and the product mixture was subjected to HPLC on a TSK amide 80 column, no appreciable degradation product was detected, and greater than 98% of the starting material was recovered. Thus, unless extensive peeling of N-glycans is catalyzed, for unknown reasons, in the course of their release from the brain glycopeptides under the conditions of reductive alkaline borohydride degradation, the immunoreactive neoglycolipids detected in the present study are likely to represent O-glycans.

The 2- and 2,6-disubstitution of the end-hexitol residues is established here with confidence for the immunoreactive oligosaccharides from the distinctive spectra of the neoglycolipids containing the hexitol remnants produced by oxidation of the end-hexitols. In the tetrasaccharide 1A2c, the end-monosaccharide is mannitol as shown by methylation analysis. Among the hexa- and octasaccharides, the presence of 2-substituted and 2,6-disubstituted end-hexitol is demonstrated, but there is no evidence for the presence of 3-substituted hexitol. These findings differ from the assignment of 3-substituted mannitol for the oligosaccharide alditols isolated from the glycopeptide moieties of brain chondroitin sulfate proteoglycans of the rat (44). In the earlier study, methylation analysis was performed on a tetrasaccharide alditol, but the partially methylated alditol acetate of Manol could not be visualized due to interfering peaks in GC; the inference of 3-substitution of the mannitol was made by comparing the mass spectra of the trimethylsilyl derivatives (and permethyl) of a disaccharide GlcNAc-Manol produced after treatments of the glycopeptides with alkaline NaBH4 or alkaline NaBD4. A fragment at m/z 205 (m/z 89 for the permethylated derivative) containing the carbon atoms 1 and 2 or 5 and 6, and arising by cleavage of different C-C bonds, showed a 10% shift in intensity to m/z 206 in the deuterated derivatives. Although this is a predicted feature of a 1-3-linked disaccharide, we have observed a similar shift (13%) in intensity m/z 205 to 206 in a 1-2-linked disaccharide standard GlcNAcbeta 1-2Manol, generated by NaBH4 and NaBD4 treatments of the reducing disaccharide2; this might represent a small degree of rearrangement involving the deuterium. We find that the spectrum of the deuterated disaccharide is very similar to that of the deuterated GlcNAcbeta 1-3Manol published earlier (44). It is desirable therefore to re-evaluate the end sequences of oligosaccharide alditols derived from the glycopeptide moieties of brain chondroitin sulfate proteoglycans. The biosynthesis of these mannose-terminating glycans is an important topic for future investigations, for there is a distinct possibility that they are products of the O-mannosylation pathway (46) described in fungi.


FOOTNOTES

*   This work was supported by Medical Research Council Program Grant E 400/622, Arthritis and Rheumatism Council Project Grant F0061, and National Institutes of Health Grants NS-13876 and MH-0012.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed. Tel.: 44-0-181-869-3460/3461; Fax: 44-0-181-869-3455; E-mail: t.feizi{at}ic.ac.uk.
1   The abbreviations used are: HPLC, high performance liquid chromatography; DHPE, L-1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine; DPPE, L-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; LSIMS, liquid secondary ion mass spectrometry.
2   C-T. Yuen, W. Chai, R. W. Loveless, A. M. Lawson, R. U. Margolis, and T. Feizi, unpublished observations.
3   Other monosubstituted hexitols would give a different combination of cleavage fragments although not all cleavages would occur with equal abundance. For example, a 3-substituted hexitol should be cleaved between C1 and C2, C4 and C5, and C5 and C6 to give R-(C2-C6), R-(C1-C4), and R-(C1-C5), respectively; a 4-substituted hexitol should be cleaved between C1 and C2, C2 and C3, and C5 and C6 to give R-(C2-C6), R-(C3-C6), and R-(C1-C5), respectively; and a 6-substituted hexitol should be cleaved between C1 and C2, C2 and C3, C3 and C4, and C4 and C5 to give R-(C2-C6), R-(C3-C6), R-(C4-C6), and R-(C5-C6), respectively.
4   A 2,4-disubstituted terminal hexitol is ruled out as it would be cleaved only between C5 and C6 to give a product containing both oligosaccharide substituents (R and R'), while a 3,6-disubstituted hexitol would be cleaved between C4 and C5 to give R-(C1-C4) and R'-(C5-C6), and is also ruled out.

ACKNOWLEDGEMENTS

We are grateful to J. R. Rosankiewicz, R. A. Carruthers, and Dr. C. G. Herbert for assistance in mass spectrometric analyses and to Drs. A. Lubineau, K. C. Nicolaou, and F. B. Jungalwala for providing synthetic oligosaccharides and glycolipid.


REFERENCES

  1. Feizi, T. (1985) Nature 314, 53-57 [Medline] [Order article via Infotrieve]
  2. Hakomori, S. (1985) Cancer Res. 45, 2405-2414 [Medline] [Order article via Infotrieve]
  3. Bevilacqua, M. P., and Nelson, R. M. (1993) J. Clin. Invest. 91, 379-387 [Medline] [Order article via Infotrieve]
  4. Drickamer, K., and Taylor, M. E. (1993) Annu. Rev. Cell Biol. 9, 237-264 [CrossRef]
  5. Feizi, T. (1993) Curr. Opin. Struct. Biol. 3, 701-710 [CrossRef]
  6. Crocker, P. R., and Feizi, T. (1996) Curr. Opin. Struct. Biol. 6, 679-691 [CrossRef][Medline] [Order article via Infotrieve]
  7. Abo, T., and Balch, C. M. (1981) J. Immunol. 127, 1024-1029 [Abstract/Free Full Text]
  8. Chou, D. K. H., Ilyas, A. A., Evans, J. E., Costello, C., Quarles, R. H., and Jungalwala, F. B. (1986) J. Biol. Chem. 261, 11717-11725 [Abstract/Free Full Text]
  9. Chou, D. K. H., Schwarting, G. A., Evans, J. E., and Jungalwala, F. B. (1987) J. Neurochem. 49, 865-873 [Medline] [Order article via Infotrieve]
  10. Ariga, T., Kohriyama, T., Freddo, L., Latov, N., Saito, M., Kon, K., Ando, S., Suzuki, M., Hemling, M. E., Rinehart, K. L., Jr., Kusunoki, S., and Yu, R. K. (1987) J. Biol. Chem. 262, 848-853 [Abstract/Free Full Text]
  11. Schachner, M., and Martini, R. (1995) Trends Neurosci. 18, 183-191 [CrossRef][Medline] [Order article via Infotrieve]
  12. Margolis, R. K., and Margolis, R. U. (1993) Experientia (Basel) 49, 429-446 [Medline] [Order article via Infotrieve]
  13. Prasadaro, N., Koul, O., Tobet, S. A., Chou, D. K., and Jungalwala, F. B. (1990) J. Neurochem. 55, 2024-2030 [Medline] [Order article via Infotrieve]
  14. Yoshihara, Y., Oka, S., Watanabe, Y., and Mori, K. (1991) J. Cell Biol. 115, 731-744 [Abstract]
  15. Jungalwala, F. B., Chou, D. K., Suzuki, Y., and Maxwell, G. D. (1992) J. Neurochem. 58, 1045-1051 [Medline] [Order article via Infotrieve]
  16. Green, P. J., Tamatani, T., Watanabe, T., Miyasaka, M., Hasegawa, A., Kiso, M., Yuen, C.-T., Stoll, M. S., and Feizi, T. (1992) Biochem. Biophys. Res. Commun. 188, 244-251 [Medline] [Order article via Infotrieve]
  17. Needham, L. K., and Schnaar, R. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1359-1363 [Abstract]
  18. Needham, L. K., and Schnaar, R. L. (1993) J. Cell Biol. 121, 397-408 [Abstract]
  19. Griffith, L. S., Schmitz, B., and Schachner, M. (1992) J. Neurosci. Res. 33, 639-648 [Medline] [Order article via Infotrieve]
  20. Hall, H., Liu, L., Schachner, M., and Schmitz, B. (1993) Eur. J. Neurosci. 5, 34-42 [Medline] [Order article via Infotrieve]
  21. Mohan, P. S., Laitinen, J., Merenmies, J., Rauvala, H., and Jungalwala, F. B. (1992) Biochem. Biophys. Res. Commun. 182, 689-696 [Medline] [Order article via Infotrieve]
  22. Burger, D., Simon, M., Perruisseau, G., and Steck, A. J. (1990) J. Neurochem. 54, 1569-1575 [Medline] [Order article via Infotrieve]
  23. Wing, D. R., Rademacher, T. W., Field, M. C., Dwek, R. A., Schmitz, B., Thor, G., and Schachner, M. (1992) Glycoconj. J. 9, 293-301 [Medline] [Order article via Infotrieve]
  24. Jaques, A. J., Opdenakker, G., Rademacher, T. W., Dwek, R. A., and Zamze, S. E. (1996) Biochem. J. 316, 427-437 [Medline] [Order article via Infotrieve]
  25. Voshol, H., van Zuylen, C. W. E. M., Orberger, G., Vliegenthart, J. F. G., and Schachner, M. (1996) J. Biol. Chem. 271, 22957-22960 [Abstract/Free Full Text]
  26. Oka, S., Terayama, K., Kawashima, C., and Kawasaki, T. (1992) J. Biol. Chem. 267, 22711-22714 [Abstract/Free Full Text]
  27. Margolis, R. K., and Margolis, R. U. (1970) Biochemistry 9, 4389-4396 [Medline] [Order article via Infotrieve]
  28. Yuen, C.-T., Lawson, A. M., Chai, W., Larkin, M., Stoll, M. S., Stuart, A. C., Sullivan, F. X., Ahern, T. J., and Feizi, T. (1992) Biochemistry 31, 9126-9131 [Medline] [Order article via Infotrieve]
  29. Takasaki, S., Mizuochi, T., and Kobata, A. (1982) Methods Enzymol. 83, 263-268 [Medline] [Order article via Infotrieve]
  30. Iyer, R. N., and Carlson, D. M. (1971) Arch. Biochem. Biophys. 142, 101-105 [Medline] [Order article via Infotrieve]
  31. Nicolaou, K. C., Bockovich, N. J., and Carcanague, D. R. (1993) J. Am. Chem. Soc. 115, 8843-8844
  32. Lubineau, A., Le Gallic, J., and Lemoine, R. (1994) Bioorgan. & Med. Chem. Lett. 2, 1143-1151 [CrossRef]
  33. Yamashita, K., Mizuochi, T., and Kobata, A. (1982) Methods Enzymol. 83, 105-126 [Medline] [Order article via Infotrieve]
  34. Feizi, T., Stoll, M. S., Yuen, C.-T., Chai, W., and Lawson, A. M. (1994) Methods Enzymol. 230, 484-519 [Medline] [Order article via Infotrieve]
  35. Lawson, A. M., Chai, W., Cashmore, G. C., Stoll, M. S., Hounsell, E. F., and Feizi, T. (1990) Carbohydr. Res. 200, 47-57 [CrossRef][Medline] [Order article via Infotrieve]
  36. Chai, W., Cashmore, G. C., Carruthers, R. A., Stoll, M. S., and Lawson, A. M. (1991) Biol. Mass. Spectrom. 20, 169-178
  37. Ciucanu, I., and Kerek, F. (1984) Carbohydr. Res. 131, 209-217 [CrossRef]
  38. Scudder, P., Lawson, A. M., Hounsell, E. F., Carruthers, R. A., Childs, R. A., and Feizi, T. (1987) Eur. J. Biochem. 168, 585-593 [Abstract]
  39. Waeghe, T. J., Darvill, A. G., McNeil, M., and Albersheim, P. (1983) Carbohydr. Res. 123, 281-304 [CrossRef]
  40. Stoll, M. S., Mizuochi, T., Childs, R. A., and Feizi, T. (1988) Biochem. J. 256, 661-664 [Medline] [Order article via Infotrieve]
  41. Chai, W., Stoll, M. S., Cashmore, G. C., and Lawson, A. M. (1993) Carbohydr. Res. 239, 107-115 [CrossRef][Medline] [Order article via Infotrieve]
  42. Krusius, T., Reinhold, V. N., Margolis, R. K., and Margolis, R. U. (1987) Biochem. J. 245, 229-234 [Medline] [Order article via Infotrieve]
  43. Chiba, A., Matsumura, K., Yamada, H., Inazu, T., Shimizu, T., Kusunoki, S., Kanazawall, I., Kobata, A., and Endo, T. (1996) J. Biol. Chem. 272, 2156-2162 [Abstract/Free Full Text]
  44. Finne, J., Krusius, T., Margolis, R. K., and Margolis, R. U. (1979) J. Biol. Chem. 254, 10295-10300 [Abstract]
  45. Hounsell, E. F., Pickering, N. J., Stoll, M. S., Lawson, A. M., and Feizi, T. (1984) Biochem. Soc. Trans. 12, 607-610 [Medline] [Order article via Infotrieve]
  46. Gentzsch, M., and Tanner, W. (1996) EMBO J. 15, 5752-5759 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.